Thank you, Linda, for your accurate rendering of what Stephanie Feldman, the Wessels analyst, said. Now the question is what type of validity to give her words?
She said: "Our sources also indicate that Zonagen, the developer of Vasomax, another oral drug to treat ED, is experiencing a 50% drop out rate in their clinical trials."
The problem with the above statement is that clinical trials have been completed, so the term "is experiencing" cannot be true. Perhaps she was confusing drop out rate with the fact that about 50% of the men in the clinical trials were not helped by Vasomax. That would be consistent with the facts as reported by PPD Pharmaco.
Ms. Feldman went on to say: "Apparently, men who are taking the highest dosage are suffering from severe vomiting and nausea. On the flip side, men who are taking the lowest and middle dosages are not getting satisfactory responses."
She continues to use the present tense. If that is what she intended, then she can only be referring to the open label studies. I was told that only the 40mg dose is being tested in the open label studies, so where did three dosages come from? If indeed three dosages are being used, why were these severe types of reactions not found in the Phase II German studies, where three dosages, including 80mg, were used, or in the Phase III studies, where 80 mg were also studied?
Ms. Feldman ended with the following: "At this point we understand that Zonagen, which initially planned to file its application last summer and again at the end of the year, is considering a new series of clinical studies."
Now what in the world would cause her to understand that? Did she talk to Joe Podolski or Martin Sutter? Perhaps Schering-Plough? More likely, her source is one of the short sellers trying to plant some disinformation. What is indisputable is that there is a sophisticated cabal of short sellers doing all they can to attack this company. As has been pointed out, some posters here seemed to know this was coming. Put two and two together and it still comes out four.
What puzzles me is that when I asked around, I was told that Wessels is a generally good source of research. I don't know this particular analyst, but her comments on Zonagen, a company she does not even follow, seems to be based on rumor and innuendo, something that readers of this board are used to.
And so it goes.
Hippias ;) |
